These drugs are just too large to slip through the skin
For patients whose constipation is limiting adherence or quality of life, individualized medical management often makes the difference between stopping therapy and long-term success
NOTE : General Substack newsletters and the microsite are free
AA received research grants and lecture or advisory board fees from MSD, AstraZeneca, Novartis, Boehringer Ingelheim, Sanofi, Mediolanum, Janssen, Novo Nordisk, Lilly, Servier and Takeda
Motley Rice supports a separate vision loss MDL Motley Rice member attorney Jonathan Orent is co-lead counsel for the pre-existing MDL and has been closely involved in shaping the litigation against Novo Nordisk and Eli Lilly